Pricing Of Zydelig And Imbruvica Will be Scrutinized After EMA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead's Zydelig and Janssen's Imbruvica have both been recommended for approval for leukemia treatment by the EMA, but with austerity still around in Europe member states will be scrutinizing these high-priced orphan drugs.